List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3234897/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction. JAMA - Journal of the American Medical Association, 2012, 308, 796.	7.4	622
2	A new framework to enhance the interpretation of external validation studies of clinical prediction models. Journal of Clinical Epidemiology, 2015, 68, 279-289.	5.0	395
3	Individual Participant Data Meta-Analysis for a Binary Outcome: One-Stage or Two-Stage?. PLoS ONE, 2013, 8, e60650.	2.5	157
4	A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data metaâ€analysis. Statistics in Medicine, 2013, 32, 3158-3180.	1.6	153
5	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial). Trials, 2012, 13, 230.	1.6	152
6	Effect of Using the HEART Score in Patients With Chest Pain in the Emergency Department. Annals of Internal Medicine, 2017, 166, 689.	3.9	149
7	Imputation of systematically missing predictors in an individual participant data metaâ€analysis: a generalized approach using MICE. Statistics in Medicine, 2015, 34, 1841-1863.	1.6	135
8	Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models. Journal of Clinical Epidemiology, 2012, 65, 686-695.	5.0	121
9	Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. Pharmacoeconomics, 2017, 35, 727-740.	3.3	116
10	Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 139-150.	0.3	105
11	A closed testing procedure to select an appropriate method for updating prediction models. Statistics in Medicine, 2017, 36, 4529-4539.	1.6	102
12	Optimal screening strategy for familial intracranial aneurysms. Neurology, 2010, 74, 1671-1679.	1.1	90
13	Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk. Circulation, 2008, 117, 2875-2883.	1.6	89
14	Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 277-286.	0.3	75
15	Growth rates of intracranial aneurysms: exploring constancy. Journal of Neurosurgery, 2008, 109, 176-185.	1.6	70
16	Metaâ€analysis and aggregation of multiple published prediction models. Statistics in Medicine, 2014, 33, 2341-2362.	1.6	55
17	The impact of the HEART risk score in the early assessment of patients with acute chest pain: design of a stepped wedge, cluster randomised trial. BMC Cardiovascular Disorders, 2013, 13, 77.	1.7	52
18	Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study. PLoS ONE, 2013, 8, e59161.	2.5	51

#	Article	IF	CITATIONS
19	The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics, 2019, 22, 8-15.	1.0	49
20	Aggregating published prediction models with individual participant data: a comparison of different approaches. Statistics in Medicine, 2012, 31, 2697-2712.	1.6	47
21	Cost-Effectiveness of Magnetic Resonance Angiography Versus Intra-arterial Digital Subtraction Angiography to Follow-Up Patients With Coiled Intracranial Aneurysms. Stroke, 2010, 41, 1736-1742.	2.0	43
22	Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage. Neurology, 2008, 70, 2053-2062.	1.1	41
23	Excess Mortality and Cardiovascular Events in Patients Surviving Subarachnoid Hemorrhage. Stroke, 2011, 42, 902-907.	2.0	41
24	Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. International Journal of Molecular Sciences, 2017, 18, 363.	4.1	39
25	Pointâ€ofâ€care testing in primary care: A systematic review on implementation aspects addressed in test evaluations. International Journal of Clinical Practice, 2019, 73, e13392.	1.7	36
26	External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. European Urology Oncology, 2018, 1, 411-417.	5.4	31
27	Lung cancer risk at low cumulative asbestos exposure: meta-regression of the exposure–response relationship. Cancer Causes and Control, 2013, 24, 1-12.	1.8	27
28	The need to balance merits and limitations from different disciplines when considering the stepped wedge cluster randomized trial design. BMC Medical Research Methodology, 2015, 15, 93.	3.1	27
29	A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 17-25.	1.4	25
30	Aiming for a representative sample: Simulating random versus purposive strategies for hospital selection. BMC Medical Research Methodology, 2015, 15, 90.	3.1	24
31	Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah. Value in Health, 2022, 25, 340-349.	0.3	23
32	How to estimate the health benefits of additional research and changing clinical practice. BMJ, The, 2015, 351, h5987.	6.0	21
33	The cost–effectiveness of point-of-care D-dimer tests compared with a laboratory test to rule out deep venous thrombosis in primary care. Expert Review of Molecular Diagnostics, 2015, 15, 125-136.	3.1	21
34	Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics, 2018, 177, 133-144.	2.7	21
35	Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands. Critical Care, 2018, 22, 293.	5.8	21
36	Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis. BMC Family Practice, 2019, 20, 8.	2.9	21

#	Article	IF	CITATIONS
37	The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care. BMC Cardiovascular Disorders, 2017, 17, 213.	1.7	20
38	From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study. BMC Medical Research Methodology, 2013, 13, 12.	3.1	19
39	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Medical Research Methodology, 2017, 17, 170.	3.1	19
40	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiology, 2018, 57, 60-67.	1.9	18
41	Health Economic Evidence of Point-of-Care Testing: A Systematic Review. PharmacoEconomics - Open, 2021, 5, 157-173.	1.8	16
42	A cost-effectiveness analysis of screening for intracranial aneurysms in persons with one first-degree relative with subarachnoid haemorrhage. European Stroke Journal, 2016, 1, 320-329.	5.5	15
43	A new selection method to increase the health benefits of CVD prevention strategies. European Journal of Preventive Cardiology, 2018, 25, 642-650.	1.8	15
44	Validation and update of a lymph node metastasis prediction model for breast cancer. European Journal of Surgical Oncology, 2018, 44, 700-707.	1.0	15
45	Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non–ST elevation myocardial infarction patients. Journal of Evaluation in Clinical Practice, 2018, 24, 31-41.	1.8	15
46	Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. European Journal of Cancer, 2020, 137, 193-203.	2.8	15
47	Incorporating published univariable associations in diagnostic and prognostic modeling. BMC Medical Research Methodology, 2012, 12, 121.	3.1	14
48	Cause-specific mortality and years of life lost in patients with different manifestations of vascular disease. European Journal of Preventive Cardiology, 2016, 23, 160-169.	1.8	14
49	Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. Breast Cancer Research and Treatment, 2019, 175, 451-458.	2.5	14
50	The ethics of cluster-randomized trials requires further evaluation: a refinement of the Ottawa Statement. Journal of Clinical Epidemiology, 2015, 68, 1108-1114.	5.0	13
51	Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands. Lung Cancer, 2019, 134, 34-41.	2.0	13
52	Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. BMC Gastroenterology, 2019, 19, 209.	2.0	13
53	Development and validation of clinical prediction models: Marginal differences between logistic regression, penalized maximum likelihood estimation, and genetic programming. Journal of Clinical Epidemiology, 2012, 65, 404-412.	5.0	12
54	Long-term health benefits and costs of measurement of carotid intima–media thickness in prevention of coronary heart disease. Journal of Hypertension, 2013, 31, 782-790.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands. BMC Medical Research Methodology, 2019, 19, 117.	3.1	12
56	Real-World Utilization of Biomarker Testing for Patients with Advanced Non–Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals. Journal of Molecular Diagnostics, 2021, 23, 484-494.	2.8	12
57	Assessing performance of a randomized versus a non-randomized study design. Contemporary Clinical Trials, 2008, 29, 293-303.	1.8	11
58	Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation. European Radiology, 2022, 32, 3067-3075.	4.5	11
59	Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. Journal of Medical Economics, 2015, 18, 76-87.	2.1	10
60	Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovascular Diabetology, 2016, 15, 48.	6.8	10
61	Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations. Medical Decision Making, 2018, 38, 888-900.	2.4	10
62	A scoping review of metamodeling applications and opportunities for advanced health economic analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 181-187.	1.4	10
63	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. Medical Decision Making, 2019, 39, 57-73.	2.4	10
64	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. Pharmacoeconomics, 2020, 38, 683-713.	3.3	10
65	External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. BJU International, 2021, 128, 236-243.	2.5	10
66	Assessing the cost-effectiveness of a routine versus an extensive laboratory work-up in the diagnosis of anaemia in Dutch general practice. Annals of Clinical Biochemistry, 2018, 55, 630-638.	1.6	9
67	The effectiveness of a routine versus an extensive laboratory analysis in the diagnosis of anaemia in general practice. Annals of Clinical Biochemistry, 2018, 55, 535-542.	1.6	9
68	The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis. Value in Health, 2018, 21, 203-209.	0.3	9
69	Validation of multisource electronic health record data: an application to blood transfusion data. BMC Medical Informatics and Decision Making, 2017, 17, 107.	3.0	8
70	Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process. Medical Decision Making, 2020, 40, 348-363.	2.4	8
71	Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer, 2021, 21, 488.	2.6	8
72	Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. Value in Health, 2020, 23, 1149-1156.	0.3	8

#	Article	lF	CITATIONS
73	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 2022, 20, 25.	2.1	8
74	Enhancing Value of Information Analyses. Value in Health, 2009, 12, 935-941.	0.3	7
75	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2017, 20, 1411-1419.	0.3	7
76	Cost-Effectiveness Analysis of the DiagnOSAS Screening Tool Compared With Polysomnography Diagnosis in Dutch Primary Care. Journal of Clinical Sleep Medicine, 2018, 14, 1005-1015.	2.6	6
77	Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist. Medical Decision Making, 2018, 38, 778-788.	2.4	6
78	The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Cancers, 2020, 12, 1120.	3.7	6
79	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and Therapy, 2021, 8, 1303-1322.	2.3	6
80	Improving early exclusion of acute coronary syndrome in primary care: the added value of point-of-care troponin as stated by general practitioners. Primary Health Care Research and Development, 2017, 18, 386-397.	1.2	6
81	Do Intraindividual Variation in Disease Progression and the Ensuing Tight Window of Opportunity Affect Estimation of Screening Benefits?. Medical Decision Making, 2009, 29, 82-90.	2.4	4
82	Expected number of asbestos-related lung cancers in the Netherlands in the next two decades: a comparison of methods. Occupational and Environmental Medicine, 2016, 73, 342-349.	2.8	4
83	Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury. Journal of Clinical Epidemiology, 2016, 70, 183-190.	5.0	4
84	Decision analytic modeling was useful to assess the impact of a prediction model on health outcomes before a randomized trial. Journal of Clinical Epidemiology, 2019, 115, 106-115.	5.0	4
85	Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening. Value in Health, 2021, 24, 206-215.	0.3	4
86	Choosing a Metamodel of a Simulation Model for Uncertainty Quantification. Medical Decision Making, 2022, 42, 28-42.	2.4	4
87	Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and COPD: protocol of the RED-CVD cluster randomised diagnostic trial. BMJ Open, 2021, 11, e046330.	1.9	4
88	How to Realize the Benefits of Point-of-Care Testing at the General Practice: A Comparison of Four High-Income Countries. International Journal of Health Policy and Management, 2021, , .	0.9	4
89	Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. BMC Medical Research Methodology, 2022, 22, 83.	3.1	4
90	An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart disease. Journal of Clinical Epidemiology, 2018, 94, 122-131.	5.0	3

#	Article	IF	CITATIONS
91	Predicted burden could replace predicted risk in preventive strategies forÂcardiovascular disease. Journal of Clinical Epidemiology, 2018, 93, 103-111.	5.0	3
92	Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalscience, 2018, 12, 825.	1.1	3
93	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics, 2020, 38, 1263-1275.	3.3	3
94	Early health technology assessment of future clinical decision rule aided triage of patients presenting with acute chest pain in primary care. Primary Health Care Research and Development, 2018, 19, 176-188.	1.2	2
95	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. Value in Health, 2021, 25, 104-115.	0.3	2
96	Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device. Rheumatology International, 2022, 42, 1565-1572.	3.0	2
97	Regarding: "Operative versus nonoperative treatment after primary traumatic anterior glenohumeral dislocation: expected-value decision analysis†appropriate assessment of uncertainty. Journal of Shoulder and Elbow Surgery, 2012, 21, e21-e23.	2.6	1
98	Cost-effectiveness Analysis of Diagnostic Tests. Neurosurgery, 2013, 73, E558-E560.	1.1	1
99	Why was this transfusion given? Identifying clinical indications for blood transfusion in health care data. Clinical Epidemiology, 2018, Volume 10, 353-362.	3.0	1
100	Preventing overuse of laboratory diagnostics: a case study into diagnosing anaemia in Dutch general practice. BMC Medical Informatics and Decision Making, 2020, 20, 178.	3.0	1
101	Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 72.e7-72.e14.	1.6	1
102	Procalcitonin to guide antibiotic stewardship in intensive care. Lancet Infectious Diseases, The, 2016, 16, 888.	9.1	0
103	The Dutch Parelsnoer Institute Cerebrovascular Disease Initiative: a retrospective study of the effects of integrating clinical care and research on costs and quality of care in patients with ischaemic stroke. BMJ Open, 2019, 9, e028290.	1.9	0
104	Developing Insights for Possible and Probable Acute Concussions Using Cluster Analysis. Journal of Neurotrauma, 2021, , .	3.4	0
105	Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy. Medical Decision Making, 2021, 41, 693-705.	2.4	0
106	Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data. Cancer Epidemiology, 2021, 75, 102008.	1.9	0